This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Lindsay J, Punekar YS, Morris J, Chung-Faye G.Health-economic analysis: cost-effectiveness of scheduled maintenace treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults. Alimentary Pharmacology and Therapeutics 28 (Suppl. 1): 76-87, No. 1, 1 Jul 2008
Rights and permissions
About this article
Cite this article
Scheduled infliximab maintenance worthy for Crohn's disease in UK. Pharmacoecon. Outcomes News 559, 11 (2008). https://doi.org/10.2165/00151234-200805590-00034
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805590-00034